In Brief: Chiron Proleukin
Executive Summary
Chiron Proleukin: Supplemental BLA filed April 14 for aldesleukin for injection to treat patients with metastatic melanoma based on studies of 266 patients who received intensive I.V. doses of interleukin-2. A 17% response rate was seen, according to presentations to the American Society of Clinical Oncology in Denver May 20. Median duration of response was 6.5 months...